BCG is indicated for intravesical immunotherapy of non–muscle-invasive bladder cancer (NMIBC) with intermediate- or high-risk of recurrence and/or progression, including carcinoma in situ; see the tables on recurrence risk (Opens in a new window) and progression risk (Opens in a new window).
https://www.urology-textbook.com/bcg-intravesical.html (Opens in a new window)
Date
November 17, 2025
0 comments
Would you like to be the first to write a comment?
Become a member of urology-textbook.com and start the conversation.
